Protara Therapeutics Stock (NASDAQ:TARA)

Revenue Ownership Financials Chart

Previous Close

$2.47

52W Range

$1.04 - $5.24

50D Avg

$2.04

200D Avg

$2.68

Market Cap

$47.65M

Avg Vol (3M)

$176.35K

Beta

1.79

Div Yield

-

TARA Company Profile

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

26

IPO Date

Oct 22, 2014

Website

TARA Performance

TARA Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	$-43.61M	$-67.06M	$-47.49M
Net Income	$-40.42M	$-64.81M	$-47.13M
EBITDA	$-43.61M	$-8.03M	$-47.25M
Basic EPS	$-3.57	$-5.76	$-4.20
Diluted EPS	$-3.57	$-5.76	$-4.20

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
SRRK	Scholar Rock Holding Corporation
MGTA	Dianthus Therapeutics, Inc.
MNPR	Monopar Therapeutics Inc.
MTCR	Metacrine, Inc.
IKNA	Ikena Oncology, Inc.
SRZN	Surrozen, Inc.
SQZ	SQZ Biotechnologies Company
VACC	Barinthus Biotherapeutics plc
VCNX	Vaccinex, Inc.
XLO	Xilio Therapeutics, Inc.
TRVI	Trevi Therapeutics, Inc.
LYRA	Lyra Therapeutics, Inc.